LOS ANGELES, Sept. 13 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on Opexa Therapeutics, Inc. (Nasdaq: OPXA) with a twelve month target price of $4.40. Ross Silver, Principal Analyst at Vista Partners stated, "Opexa's lead clinical candidate Tovaxin®, an autologous cellular immunotherapy for the treatment of Multiple sclerosis, has shown promising clinical data to date. In addition, the company's stem cell therapy is partnered with Novartis. Dendreon's Provenge®, the first FDA-approved autologous cellular immunotherapy, has increased awareness and acceptance for this therapeutic approach and likely increased Opexa's value amongst potential partners."
To download a FREE copy of the Opexa Therapeutics, Inc. research report, please visit www.vistap.com/research and complete the research form to gain access to the report.
About Vista Partners:
With offices in California and Oregon, Vista Partners LLC is one of the fastest growing independently owned research and consulting firms in the United States. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking.
SOURCE Vista Partners